Komori
Earnings presentation4932ALMADO,INC.Materials and Chemicals

Earnings Presentation Materials for the Fiscal Year Ending March 2026

For the fiscal year ended March 2026, net sales increased 19.4% year on year, while operating profit declined 27.6%. The earnings forecast for the fiscal year ending March 2027 is undetermined because the impact of raw material and logistics costs cannot be reasonably estimated.

Worth reading
64In focus
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
19.4
Year-on-year change in net sales (%)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Earnings presentationFiscal year ending March 2026, full year9 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales10,118 million yen+19.4%
Operating profit685 million yen-27.6%
Ordinary income689 million yen-26.4%
Net income518 million yen-20.3%
Selling, general and administrative expenses6,938 million yen
Gross Profit Margin
Rate75.3%
Year-on-year change (points)+5.4 percentage points
Results for the three months of the current quarter
Net Sales
1,991 million yen
Operating profit
535 million yen
Ordinary income
529 million yen
Net income for the current fiscal year
408 million yen
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Both net sales and operating profit achieved the revised plan
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in direct-sales revenue+¥2,162 million
  • Decrease in TV shopping revenue-¥250 million
  • Increase in general retail revenue+¥394 million
  • Decrease in OEM revenue-¥664 million
  • TV shopping revenue fell short of budget due to fewer broadcasts of major programsfrom ¥1,350 million to ¥939 million
New initiatives
  • Shift to a growth model centered on product competitiveness and eggshell membrane research
  • Continue launching high-value-added products through research and development
  • Optimize the channel portfolio
  • Strengthen promotion of existing products and increase the number of new products launched
  • Expand into TV shopping programs on terrestrial television networks
  • Change in management
Key KPIsA metric the company considers important as a management benchmark.
  • Number of new customers acquired167% of the previous year (+67.1%)
  • Subscription members126,121 people
    Year on year against the same period last year+33.9%
  • Annual CPA96.6% of the previous year
    Year on year against the same period last year-3.4%
  • Number of broadcasts of major programs4 broadcasts
    Year on year against the same period last yearHalved from 8 broadcasts
  • General retail drugstore sales127% of the previous year
  • General retail variety store sales255% of the previous year
  • Co-op salesApproximately 6 times the previous year
  • OEM sales to existing customers-42.6% of the previous year
Unit price and quantity metricsThese figures show sales broken down by price and volume.
The number of new customers acquired and CPA are provided
Segment results
  • Direct sales
    Net Sales7,417 million yen
    Year on year against the same period last year+41.1%
  • TV mail-order sales
    Net Sales939 million yen
    Year on year against the same period last year-21.1%
  • Third-party sales
    Net Sales1,761 million yen
    Year on year against the same period last year-13.3%
  • General retail
    Net Sales866 million yen
    Year on year against the same period last year+83.5%
  • OEM
    Net Sales894 million yen
    Year on year against the same period last year-42.6%
Financial targets
ROE actual: 36.2%; equity ratio actual: 40.1%. Numerical targets: Not disclosed
Orders received and order backlog
Developed 2 new OEM customers. Amount: Not disclosed
Number of stores and locations
Number of stores carrying the products: As of the end of March 2026, CELLULA (serum and men's products) was available at 3,060 stores and NOMULAB (protein) at 2,469 stores. As of 15 May 2026, NOMULAB (protein) and Inner Force were available at 9,516 stores. The number of store openings and closures during the period was Not disclosed
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredFiscal year ending March 2026, full year
Net Sales10,118 million yen (YoY +19.4%)
Operating profit685 million yen (YoY -27.6%)
Ordinary income689 million yen (YoY -26.4%)
Net income518 million yen (YoY -20.3%)
Gross Profit MarginRate 75.3% / Year-on-year change (points) +5.4 percentage points
Selling, general and administrative expenses6,938 million yen
Results for the three months of the current quarterNet Sales 1,991 million yen / Operating profit 535 million yen / Ordinary income 529 million yen / Net income for the current fiscal year 408 million yen
Self-assessment against the planBoth net sales and operating profit achieved the revised plan
Segment resultsSegment Direct sales / Net Sales 7,417 million yen / Year on year against the same period last year +41.1%, Segment TV mail-order sales / Net Sales 939 million yen / Year on year against the same period last year -21.1%, Segment Third-party sales / Net Sales 1,761 million yen / Year on year against the same period last year -13.3%, Segment General retail / Net Sales 866 million yen / Year on year against the same period last year +83.5%, Segment OEM / Net Sales 894 million yen / Year on year against the same period last year -42.6%
Breakdown of Factors Affecting the ChangeFactors Increase in direct-sales revenue / Amount +¥2,162 million, Factors Decrease in TV shopping revenue / Amount -¥250 million, Factors Increase in general retail revenue / Amount +¥394 million, Factors Decrease in OEM revenue / Amount -¥664 million, Factors TV shopping revenue fell short of budget due to fewer broadcasts of major programs / Amount from ¥1,350 million to ¥939 million
Key KPIsIndicator name Number of new customers acquired / Value 167% of the previous year (+67.1%), Indicator name Subscription members / Value 126,121 people / Year on year against the same period last year +33.9%, Indicator name Annual CPA / Value 96.6% of the previous year / Year on year against the same period last year -3.4%, Indicator name Number of broadcasts of major programs / Value 4 broadcasts / Year on year against the same period last year Halved from 8 broadcasts, Indicator name General retail drugstore sales / Value 127% of the previous year, Indicator name General retail variety store sales / Value 255% of the previous year, Indicator name Co-op sales / Value Approximately 6 times the previous year, Indicator name OEM sales to existing customers / Value -42.6% of the previous year
Unit price and quantity metricsThe number of new customers acquired and CPA are provided
Number of stores and locationsNumber of stores carrying the products: As of the end of March 2026, CELLULA (serum and men's products) was available at 3,060 stores and NOMULAB (protein) at 2,469 stores. As of 15 May 2026, NOMULAB (protein) and Inner Force were available at 9,516 stores. The number of store openings and closures during the period was Not disclosed
Financial targetsROE actual: 36.2%; equity ratio actual: 40.1%. Numerical targets: Not disclosed
Orders received and order backlogDeveloped 2 new OEM customers. Amount: Not disclosed
New initiativesShift to a growth model centered on product competitiveness and eggshell membrane research, Continue launching high-value-added products through research and development, Optimize the channel portfolio, Strengthen promotion of existing products and increase the number of new products launched, Expand into TV shopping programs on terrestrial television networks, Change in management
Items this document does not state (13)
Operating profit marginFull-year earnings forecastProgress against full-year forecastNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Growth in the direct-sales and general retail businesses drove the increase in net sales. However, the decline in sales in the TV shopping and OEM businesses reduced the contribution of higher-margin businesses, while investments in personnel and advertising, as well as promotional and logistics costs, increased, resulting in lower profit. The earnings forecast for the fiscal year ending March 2027 remains undetermined because the impact of unstable raw material procurement amid the situation in the Middle East and rising raw material and logistics costs is difficult to estimate reasonably.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Earnings Presentation Materials for the Fiscal Year Ending March 2026 | ALMADO,INC. (4932) timely disclosure | Komori